ArticleDrug design, development and therapy2026
Model-Informed Precision Dosing of Tacrolimus Initial Dosage Optimization in Membranous Nephropathy Patients.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Due to the therapeutic window of tacrolimus is narrow and there are significant individual differences in metabolism, a uniform dosage is prone to result in poor efficacy or increased toxic side effects. This study aimed to explore tacrolimus initial dosage optimization in membranous nephropathy (MN) patients based on model-informed precision dosing (MIPD). Methods: Population pharmacokinetic model, an effective tool of MIPD, was constructed using the non-linear mixed effect modeling approach implemented in NONMEM software, which encompassed a range of patient-related data, including demographic characteristics, physiological and biochemical test results, as well as details regarding concurrent medications. Results: From the aspect of individualized drug administration, in adult MN patients, the initial dosages of tacrolimus were 0.06 mg/kg, 0.04 mg/kg for patients weighted 50-53 kg, 53-100 kg, respectively. In pediatric MN patients, the initial dosages of tacrolimus were 0.12 mg/kg, 0.10 mg/kg, 0.08 mg/kg, 0.06 mg/kg for patients weighted 10-12.7 kg, 12.7-16.4 kg, 16.4-26.7 kg, 26.7-40 kg, respectively. Conclusion: This study was the first time to simultaneously recommend the optimal initial dosage of tacrolimus for both adult and pediatric MN patients based on MIPD. Moreover, the dosage required for pediatric MN patients was higher than that for adult MN patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.